"Shares of Altimmune (NASDAQ:ALT) surged 35.4% over the past week, coinciding with a dramatic shift in retail investor sentiment on Reddit. The clinical-stage biotech develops treatments for metabolic diseases and became one of the highest-rated stocks in social sentiment tracking after the FDA granted Breakthrough Therapy Designation for its lead drug pemvidutide on January 16. Mentions of Altimmune on Reddit increased sharply, with users sharing high-conviction positions."
"BTD CONFIRMED - Yesterday, the FDA granted them Breakthrough Therapy Designation (BTD) for MASH. This is huge. It means the FDA sees 'substantial improvement' over existing therapies."
"BTD IS A HUGE FUCKING DEAL, only around 1/3 of applications gets accepted, and it tells big Pharma, FDA wants this drug, come fucking buy."
"I've been in this stock since $3.50, added more at $4.20, and I'm not selling until we hit double digits or get bought out. This is my conviction play for 2026."
Altimmune is a clinical-stage biotech focused on metabolic disease treatments, with lead candidate pemvidutide receiving FDA Breakthrough Therapy Designation on January 16. Shares rose 35.4% over one week amid a surge in Reddit attention and bullish social sentiment tracking. A high-engagement r/wallstreetbets post claimed the BTD signals substantial improvement over existing therapies and could attract big pharma acquisition interest. Retail traders pointed to four consecutive 2025 quarterly earnings beats, a 45% year-over-year narrowing in annual losses to negative $0.74 per share, and the January 2026 hiring of CEO Jerome Durso as catalysts for upside.
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]